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Abstract
Background: Oncogene amplification and overexpression occur in tumor cells. Amplification status may provide
diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24,
11q13, 17q12 and 20q13 are recurrently amplified in breast cancers.
Methods: To assess the frequencies and clinical impact of amplifications, we analyzed 547 invasive breast tumors
organized in a tissue microarray (TMA) by fluorescence in situ hybridization (FISH) and calculated correlations with
histoclinical features and prognosis. BAC probes were designed for: (i) two 8p12 subregions centered on RAB11FIP1 and
FGFR1 loci, respectively; (ii) 11q13 region centered on CCND1; (iii) 12p13 region spanning NOL1; and (iv) three 20q13
subregions centered on MYBL2, ZNF217 and AURKA, respectively. Regions 8q24 and 17q12 were analyzed with MYC and
ERBB2 commercial probes, respectively.
Results: We observed amplification of 8p12 (amplified at RAB11FIP1 and/or FGFR1) in 22.8%, 8q24 in 6.1%, 11q13 in
19.6%, 12p13 in 4.1%, 17q12 in 9.9%, 20q13Z (amplified at ZNF217 only) in 9.9%, and 20q13Co (co-amplification of two
or three 20q13 loci) in 8.5% of cases. The 8q24, 12p13, and 17q12 amplifications were correlated with high grade. The
most frequent single amplifications were 8p12 (9.8%), 8q24 (3.3%) and 12p13 (3.3%), 20q13Z and 20q13Co (1.6%) regions.
The 17q12 and 11q13 regions were never found amplified alone. The most frequent co-amplification was 8p12/11q13.
Amplifications of 8p12 and 17q12 were associated with poor outcome. Amplification of 12p13 was associated with basal
molecular subtype.
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Conclusion: Our results establish the frequencies, prognostic impacts and subtype associations of various amplifications
and co-amplifications in breast cancers.
Background
Amplification is a frequent and important mechanism for
oncogene overexpression in breast tumor cells. Several
amplified regions may participate to breast tumor initia-
tion and/or progression [1]. Chromosomal regions 8p12,
8q24, 11q13, 17q12 and 20q13 are amplified in a consist-
ent proportion of breast tumors [2-5]. The 12p13 region
was also found amplified in some breast tumors [6,7].
Amplification status may be determined in clinics as an
indicator of prognosis or before applying a specific treat-
ment: ERBB2 amplification, found in 15 to 25% of breast
cancers, is a marker of adverse prognosis and encodes a
tyrosine kinase receptor that is the target of trastuzumab
(Herceptin) [8-10]. Amplifications at 8p12, 8q24, 11q13,
12p13, and 20q13 have also potential clinical interest as
prognosis markers and/or therapeutic targets. Amplifica-
tion of the 8p12 region is found in around 15% of breast
cancers [11-13]. Although the identity of the driver genes
has not been definitely established, the importance of the
FGFR1 tyrosine kinase receptor gene has been suggested
[5,14]. Amplification of this region has an adverse impact
on prognosis in breast cancer [5]. MYC is localized in
8q24 and encodes a nuclear protein that plays a role in
cell cycle progression. Amplification of 8q24 occurs in up
to 20% of breast cancers and is associated with a poor
clinical outcome [15-21]. CCND1 localized in 11q13
encodes cyclin D1, which is active during the G1 phase of
the cell cycle. Amplification of CCND1 occurs in 10 to
30% of breast cancers [3,22-24]. Amplification of 12p13
is not a frequent event in breast cancers but genomic stud-
ies indicate its potential importance in basal breast can-
cers [7,25]. The 20q13 chromosomal region is amplified
in 5% to 20% in breast tumors and its prognosis impact is
unclear [26-29]. Several potential oncogenes have been
suggested, including MYBL2 [23,30], AURKA [31], and
ZNF217 [32-34].
To assess the frequencies and to evaluate the impact on
prognosis of amplifications and co-amplifications, we
analyzed 547 breast tumors organized in a tissue microar-
ray (TMA) by fluorescence in situ hybridization (FISH)
with probes covering amplified regions. BAC probes were
designed for: (i) two 8p12 subregions [5] centered on
RAB11FIP1 and FGFR1 loci, respectively; (ii) 11q13
region centered on CCND1; (iii) 12p13 region spanning
NOL1; and (iv) three 20q13 subregions [29] centered on
MYBL2, ZNF217 and AURKA, respectively. Regions 8q24
and 17q12 were analyzed with MYC and ERBB2 commer-
cial probes, respectively.
Methods
Patients and histological samples
We studied a consecutive series of 547 unilateral localized
invasive breast carcinomas from women treated at the
Institut Paoli-Calmettes between October 1987 and
December 1999. According to the WHO classification,
this series comprised 386 ductal, 72 lobular, 37 tubular, 8
medullary carcinomas and 44 other histological types.
They were obtained after informed consent and stored in
an anonymous fashion according to an approval of the
local Ethics Committee. The Ethics Committee of the
Institut Paoli-Calmettes (Marseille's Cancer Institute)
approved the use of these specimens and the data in
research. The average age at diagnosis was 59 years (range
25–94). Raw survival data were either obtained from the
cancer registry of the Institut Paoli-Calmettes or collected
from the patients attending physicians. The pathologic
stage, tumor diameter, and nodal status were obtained
from the primary pathology reports. A total of 254 tumors
were associated with lymph node invasion and 403 were
positive for estrogen receptor. All slides from all tumors
were reviewed by one of two pathologists (J. J. and E.C.J.)
to define the various histoclinical factors collected for this
series. They included patient age, invasive histological
type, pathological tumor size, Scarff-Bloom-Richardson
(SBR) grade (I to III), peritumoral vascular invasion, axil-
lary lymph node status, estrogen receptor expression (ER),
progesterone receptor expression (PR), P53 status, as eval-
uated by immunohistochemistry (IHC) with a positivity
cut-off value of 1%, ERBB2 status, evaluated by IHC with
the 0-3+ score as illustrated by the HercepTest kit scoring
guidelines (DakoCytomation, Coppenhagen, Denmark),
and Ki67 status as evaluated by IHC with a positive cut-off
value at 20%. This study was approved and executed in
compliance with our institutional review board.
Tissue microarray construction
Tissue microarray (TMA) was prepared as described previ-
ously [35]. Five-µm sections of the resulting TMA block
were made and used for fluorescence in situ hybridization
(FISH) and IHC analysis after transfer onto glass slides.
Fluorescence In Situ Hybridization on TMA analysis
To characterize the 8q24 and 17q12 amplified regions,
FISH on TMA was done according to the histology FISH
instructions of DakoCytomation with the MYC probe and
HER2 FISH pharmDx™ kit (DakoCytomation, Coppenha-
gen, Denmark). To characterize the 8p12, 11q13, 12p13,
and 20q13 amplified regions, FISH on TMA was done
according to published protocols [36,37]. Two 8p12 sub-
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regions centered on RAB11FIP1 and FGFR1 loci, respec-
tively, were analyzed. From telomere to centromere, the
different BAC pools were constituted as follows: BAC pool
1 (RAB11FIP1 region): RP11-863K10 (AC138356;
chr8:37,630,477-37,820,753), RP11-113G10
(chr8:37,715,876-37,881,776), RP11-457O21
(chr8:37,881,796-38,044,340); BAC pool 2 (FGFR1
region): RP11-90P5 (AC084024.17; chr8:38,091,019-
38,226,422), RP11-513D5 (AC087362.13;
chr8:38,216,677-38,358,846), RP11-100B16
(chr8:38,358,839-38,522,417), RP11-675F6
(AC069120.9; chr8:38,485,749-38,646,922). The 11q13
region centred on CCND1 was analyzed with the follow-
ing combination of BAC pools, from centromere to tel-
omere: RP11-300I6 (AP001888; chr11:69,162,462-
69,323,966), RP11-643C9 (chr11:69,297,662-
69,494,887), RP11-626H12 (AP003555;
chr11:69,478,620-69,600,219). The 12p13 region span-
ning NOL1 region was analyzed with, from telomere to
centromere, RP5-940J5 (AC006064; chr12:6,422,311-
6,594,917), RP11-433J6 (AC135892; chr12:6,579,330-
6,755,900), RP11-578M14 (chr12:6,699,832-6,884,088)
BAC pool. Three 20q13 subregions of amplification corre-
sponding to MYBL2, ZNF217 and AURKA loci were ana-
lyzed with locus-specific BAC pools, from centromere to
telomere : MYBL2 locus BAC pool : RP11-69I10
(chr20:41,467,083-41,631,733), RP11-153L9
(chr20:41,659,456-41,808,516), RP5-1030M6
(AL035089; chr20:41,816,168-41,989,971); ZNF217
locus BAC pool : RP11-91L1 (chr20:51,421,217-
51,572,829), RP4-724E16 (AL157838;
chr20:51,561,511-51,690,363), RP11-299C12
(chr20:51,647,272-51,837,964); and AURKA locus BAC
pool : RP11-380D15 (AL139824; chr20:54,122,911-
54,316,054), RP5-1167H4 (AL121914;
chr20:54,336,458-54,472,150), RP5-1153D9
(AL109806; chr20:54,472,051-54,566,171). Genomic
information was taken from the UCSC Genome Browser
on Human (March 2006 Assembly), which is based on
NCBI Build 35 (National Center for Biotechnology Infor-
mation, U.S. National Library of Medicine 8600 Rockville
Pike, Bethesda, MD, USA).
DNA from BAC clones were purified, labeled and individ-
ually verified for their specificity of their addressed
regions. All BAC clones were obtained from the BACPAC
resource (Children's Hospital Oakland – BACPAC
Resources, Oakland, CA, USA). After counterstaining with
Vectashield containing 4,6-diamidino-2-phenylindole
(DAPI) (Vector, Burlingame, CA, USA), images were ana-
lyzed with a microscope (DMRXA, Leica Microsystèmes,
Marseille, France), captured with a CCD camera, filtered
and processed with ISIS software (In Situ Imaging Sys-
tems, Metasystems Hard- und Software GmbH, Alt-
lussheim, Germany)[38].
Fluorescence was scored on a minimum of 50 nuclei per
tumor. The 50 nuclei of cancer cells were representative of
the overall cell heterogeneity of the tumor. For each
region analyzed, two observers read the TMA independ-
ently. The region analyzed was considered as amplified
when the number of BAC pool signal was >5 in the cell.
Tumors were defined as amplified when 10% or more of
tumor cells showed such amplification.
Immunohistochemistry analysis
The characteristics of the antibodies used are listed in
Table 1. IHC was done as previously described [35], using
LSAB2 kit in the autostainer (Dako Autostainer, Copenha-
gen, Denmark). Results were evaluated under a light
microscope by two pathologists (EC-J, JJ) and scored by
the quick score (QS) as previously done [35], except for
ERBB2 status, which was evaluated with the Dako scale
(HercepTest kit scoring guidelines). For each tumor, the
mean of the score of a minimum of two core biopsies was
calculated.
Statistical methods
Amplification data were summarized by frequencies and
percentages. Clinical data were dichotomized as follows:
Amplicon: amplified vs. non-amplified, grade: I vs. II/III,
age: <50 vs. ≥ 50, tumor size: pT1 vs. pT2/pT3, peritu-
moral vascular invasion: absent vs. present, estrogen
receptor and progesterone receptor: negative vs. positive,
Ki67: <20 vs. ≥ 20 and axillary lymph node: negative vs.
positive.
The association between two categorical variables was
examined using Fisher's exact or χ2 tests. The primary end-
point was the metastasis-free survival (MFS), which was
Table 1: List of proteins tested by immunohistochemistry and characteristics of the corresponding antibodies.
Protein Antibody Origin Clone Dilution
Estrogen receptor mmab Novocastra Laboratories 6F11 1/60
Progesterone receptor mmab DakoCytomation PgR 636 1/80
ERBB2 rpab DakoCytomation HercepTest 1/400
P53 mmab Immunotech DO-1 1/4
Ki67 mmab DakoCytomation MIB-1 1/100
mmab, mouse monoclonal antibody; rpab, rabbit polyclonal antibody
BMC Cancer 2006, 6:245 http://www.biomedcentral.com/1471-2407/6/245
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defined by the time interval between the diagnosis of
breast cancer and a distant metastasis. Metastasis-free
patients were right censored at the date of the last follow-
up, death, recurrence of local or regional disease, or devel-
opment of a second primary cancer. Survival curves were
derived from Kaplan-Meier estimates and compared by
log-rank test. Significant changes of relative risks of metas-
tasis according to the amplification status were explored
using Cox's proportional hazard models in univariate and
multivariate analysis. Multivariate models were built
using a backward stepwise selection of variables to mini-
mize the Akaike Information Criterion. All results are pre-
sented with their 95% confidence intervals. Statistical
tests were two-sided at the 5% level of significance. All the
statistical analyses were done using R.2.3.0 statistical soft-
ware [39].
Results
Frequencies of amplifications and co-amplifications
Six regions of amplification were analyzed: 8p12 (ampli-
fied at least at one locus: RAB11FIP1 and/or FGFR1), 8q24
(MYC), 11q13 (CCND1), 12p13 (NOL1), 17q12
(ERBB2), and 20q13Co (co-amplification of either two of
three loci: MYBL2, ZNF217 and AURKA, or all three)
regions. For the 20q13 region, in regard to the significant
impact of ZNF217 amplification on disease evolution
[29], we decided to distinguish the amplified subregion
20q13Z centered on ZNF217. To assess the frequencies of
the 8p12, 8q24, 11q13, 12p13, 17q12 and 20q13 ampli-
fications we used FISH on TMA with specific probes. The
number of interpretable cases varied between different
FISH experiments (Figure 1). All TMA sections were only
hybridized once. Reasons for non-informative results
were: lack of tissue on the TMA, absence of unequivocal
tumor cells, or non-interpretable hybridization data.
Among the informative cases, the frequency of amplifica-
tion was 22.8% for 8p12, 6.1% for 8q24, 19.6% for
11q13, 4.1% for 12p13, 9.9% for 17q12, 9.9% for 20q13Z
and 8.5% for 20q13Co regions (Figure 1). More in detail,
the amplification frequencies of subregions centered on
RAB11FIP1 and FGFR1 (8p12) as well as on MYBL2,
ZNF217 and AURKA (20q13) loci are listed in Table 2.
The highest amplication frequencies were obtained with
RAB11FIP1 and ZNF217 subregions for 8p12 and 20q13,
respectively.
We then looked at the distribution of the frequency of
amplifications and co-amplifications. Overall, only 128
cases were informative for all the regions analyzed. A total
of 57.4% of cases showed no amplification. The frequency
of single amplifications was 9.8% for 8p12, 3.3% for 8q24
and 12p13, 1.6% for 20q13Co and 20q13Z. The 11q13 and
17q12 regions were never found amplified alone. The fre-
quency of co-amplifications was 8.2% for 8p12/11q13,
3.3% for 11q13/17q12, 1.6% for 17q12/20q13Co, 11q13/
20q13Co, 11q13/20q13Z/20q13Co, 8q24/11q13/17q12,
8q24/20q13Z/20q13Co, 8p12/11q13/12p13 and 8p12/
11q13/20q13Z/20q13Co (Figure 2). We also looked for
associations between amplified regions. The 11q13/
20q13Co, 12p13/20q13Z and 8p12/11q13 co-amplifica-
tions were among the most strongly correlated [see Addi-
tional file 1].
Correlation of amplified regions with histoclinical factors
We next examined the relation between amplifications
and histoclinical factors [see Additional file 2]. We did not
find any association between amplified regions and age,
histological type and pathological tumor size. Amplifica-
tion of 8q24, 12p13, 17q12 and 20q13Co regions were
correlated with high grade. Amplification of 8p12, 12p13
and 17q12 were correlated with a high proliferation
index. Amplification of 8q24, 12p13, 17q12, and 20q13Z
were associated with ER and/or PR negativity. The
20q13Co amplification was associated with axillary lymph
node invasion.
Correlation of amplified regions with clinical outcome
We then examined the impact of amplifications and co-
amplifications on clinical outcome. We did univariate
analyses to determine the impact of each individual
amplified region on the MFS. The 8p12 and 17q12 ampli-
fications but not the others were associated with clinical
outcome (Table 3). Both were associated with decreased
five-year MFS in the whole population and in N- patients
(Figure 3A–D).To estimate the impact of co-amplification
on MFS we did a multivariate analysis of significant
amplifications in univariate analysis followed by a step-
wise selection. We found that co-amplification of 8p12/
17q12 was associated with a poor outcome in N- patients
(Figure 3E).
We further evaluated the importance of the amplifications
as prognosis markers. We did a Cox multivariate analysis
of MFS. The values for amplification, grade, age, tumor
size, peritumoral vascular invasion, ER, PR, and Ki67 were
considered as categorical variables. Amplification status of
8p12 remained significant as well as Ki67 status according
to the Akaike Information criterium when dichotomized
amplified vs. non-amplified and <20 vs. ≥ 20 in N-
patients (Table 4). The relative risk of recurrence was 2.52
for 8p12-amplified disease compared to non-8p12-ampli-
fied disease (p = 0.15).
Correlation of amplified regions with molecular subtypes
Five main molecular subtypes (luminal A, luminal B,
basal, ERBB2-overexpressing, and normal-like) have been
identified by gene expression profiling of breast tumor
samples using an intrinsic set of ~500 genes [40,41]. We
determined the subtype of our samples by both mRNA
BMC Cancer 2006, 6:245 http://www.biomedcentral.com/1471-2407/6/245
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Amplification regions and FISH probesFigure 1
Amplification regions and FISH probes. Schematic representation of the six regions analyzed with probes used in FISH 
experiments and the main corresponding genes. The number of informative cases and the percentage (frequency) of amplifica-
tions of each analyzed region is given in the table.
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and protein analyses (not shown). The 11q13 amplifica-
tion was strongly correlated with the luminal A subtype (p
value = 0.00029) and negatively correlated with the basal
subtype (p value = 0.005633), whereas the 12p13 ampli-
fication was correlated with the basal subtype (p value =
0.020). As expected, the 17q12 amplification was corre-
lated with the ERBB2 subtype (p value = 2.061e-06)
(Table 5).
Discussion
Several chromosomal regions are frequent targets for gene
amplification in breast cancers. Oncogene activation and
genomic instability associated with this process may play
Table 2: 8p12 and 20q13 subregional amplification frequencies
Region of amplification Gene regions Number of FISH informative cases % of tumors with amplification
8p12 RAB11FIP1 279 13.3%
FGFR1 319 9.4%
20q13 MYBL2 265 5.7%
ZNF217 233 9.9%
AURKA 282 3.5%
Co-amplification networkFigure 2
Co-amplification network. Schematic representation of frequencies of single amplifications and co-amplifications in 128 
breast tumors samples. The size of spheres represents the frequency of region amplified as single. Lines of the same color rep-
resent co-amplification and the thickness of lines represents the frequency of the co-amplification: small: 1.6%, medium: 3.3%, 
large: 8.2%. For instance, the pink line linking 11q13, 8p12, 20q13Co and 20q13Z represents a co-amplification of all these 
regions found in 1.6% of informative cases (N = 128).
BMC Cancer 2006, 6:245 http://www.biomedcentral.com/1471-2407/6/245
Page 7 of 13
(page number not for citation purposes)
a role in tumor initiation and/or progression. Moreover,
amplification may have prognostic and/or therapeutic sig-
nificance for patients with breast cancer. However, few
studies have looked at multiple amplifications and their
potential correlations with tumor features and patient
outcome [3,4].
Using FISH on TMA, we assessed the frequency of six
amplifications, their potential association and their
impact on clinical outcome. FISH technique is an easy and
rapid method for amplification detection [42] and may
provide prognostic information sometimes superior to
other methods [43].
Frequency of amplifications and correlations with 
prognosis
The most frequent amplification and co-amplification
involved the 8p12 region. Several studies have shown that
8p12 is a common region of amplification and may har-
bor important breast cancer oncogenes [5,44-46]. This
region, like other "hot spots" for gene amplification, may
contain several genes that contribute to cell transforma-
tion. Because the exact 8p loci of significance are not
known, we analyzed two subregions of 8p12 spanning
many potentially relevant genes [5,44-46]. The two subre-
gions covered genes that are amplified and most of them
are overexpressed [5]. The frequency of 8p12 amplifica-
tion in our breast tumor series was greater than the 10–
15% commonly reported in literature, but similar to that
recently reported by Garcia et al. (2005) [45]. Our results
strengthen the idea that the 8p amplification, when all
subregions are combined, may occur in a higher number
of breast cancer than published so far. The 8p amplifica-
tion was correlated with the amplification of 11q13
region: while 24.6% of tumors contained either amplified
8p12 region or 11q13 region, simultaneous amplification
of both was seen in 10.8%. This result is in agreement
with a previous study [47,48]. This suggests a coordinated
mechanism of amplification and oncogene activation,
and some kind of relation between proteins encoded by
genes from the two regions. The 8p12 amplification
tended to have aggressive tumor features such as high pro-
liferative index and high SBR grade, but no association
with histological subtype was found. With respect to prog-
nosis, the 8p amplification was a significant predictor of
reduced MFS. Multivariate analyses indicated that ampli-
fication of 8p12 added to the prognostic power of Ki67
status to define high risk N- patients. Our findings are
consistent with the idea that 8p12 is a common region of
amplification that may play a role in tumor behavior and/
or pathogenesis. Previous analysis of 8p12 subregional
amplifications in breast cancer [5] pointed to the ampli-
fied FGFR1 subregion as the best prognostic marker of bad
disease evolution among other 8p amplifications. The
identification of the best candidate drivers or the best
therapeutic targets could refine the impact of the 8p12
amplification on survival and help determine which pop-
ulation should be targeted.
Table 3: Cox univariate analyses of metastasis-free survival.
Region of amplification Population 5-year M FS [95% CI] Hazard ratio [95% CI] p-value
W hole N + N - With amplification Without amplification
8p12 + 68.75 [56.73–83.3] 82.4 [76.6–88.7] 2.25 [1.28–3.93] 0.0046
8p12 + 63.2 [46.6–85.6] 72.6 [63–83.67] 1.87 [0.95–3.71] 0.071
8p12 + 73.77 [57.59–94.49] 91.33 [85.37–97.70] 2.98 [1.1–8.06] 0.031
8q24 + 78.6 [59.8–100] 82.61 [77.63–87.92] 0.825 [0.25–2.75] 0.75
8q24 + 75 [50.3–100] 74.53 [66.32–83.75] 0.728 [0.17–3.04] 0.66
8q24 + 83.3 [58.3–100] 89.55 [84.09–95.36] 0.825 [0.09–7.66] 0.87
11q13 + 75.93 [65.28–88.31] 83.95 [79.18–89] 1.46 [0.8–2.67] 0.22
11q13 + 75.72 [61.54–93.17] 74 [65.7–83.4] 0.962 [0.44–2.1] 0.92
11q13 + 76.02 [60.88–94.92] 91.72 [86.91–96.80] 2.46 [0.93–6.48] 0.069
12p13 + 91.67 [77.29–100] 82.23 [77.85–86.85] 0.427 [0.06–3.08] 0.4
12p13 + 100 [100-100] 72.14 [64.84–80.26] * 1
12p13 + 83.3 [58.3–100] 91.28 [86.85–95.94] 2.46 [0.32–18.75] 0.39
17q12 + 64.7 [47.5–88.2] 83.92 [79.28–88.83] 2.09 [1.02–4.26] 0.044
17q12 + 68.2 [48.6–95.7] 75.37 [67.54–84.10] 1.24 [0.52–2.95] 0.63
17q12 + 55.6 [27.4–100] 91.25 [86.44–96.33] 4.2 [1.18–14.95] 0.027
20q13Z + 85.4 [71.27–100] 79.43 [73.82–85.47] 0.57 [0.18–1.83] 0.35
20q13Z + 90.91 [75.41–100] 63.98 [54.65–74.89] 0.186 [0.03–1.35] 0.097
20q13Z + 79.5 [57.7–100] 93.05 [88.18–98.19] 2.58 [0.55–12.15] 0.23
20q13Co + 90.43 [78.63–100] 79.80 [74.71–85.24] 0.364 [0.09–1.51] 0.16
20q13Co + 87.84 [73.37–100] 66.80 [58.20–76.66] 0.276 [0.07–1.15] 0.076
20q13Co + 100 [100-100] 90.40 [85.35–95.75] * 1
*No event in the amplified group
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The MYC gene on 8q24 encodes a transcriptional regula-
tor whose expression is strongly associated with cell pro-
liferation. MYC amplification occurs in several types of
cancers [49,50]. We found that the incidence of MYC
amplification was in the range of those described previ-
ously [19]. About 13% of tumors contained either ampli-
fied MYC or ERBB2, whereas simultaneous amplification
of both was seen in 1.9%. About 22% of tumors con-
tained either amplified MYC or CCND1, whereas simulta-
neous amplification of both was found in 4.2%. MYC
amplification was correlated with high grade and tended
to be associated with high proliferation index, in agree-
ment with previous studies [19]. Although the expression
of the MYC protein is stimulated by estrogen and down-
regulated by tamoxifen in hormone-responsive breast
tumors in vitro [51-54], we found that MYC amplification
Table 4: Cox multivariate analysis of metastasis free survival for patients without axillary lymph node invasion.
Variable Coefficient value Hazard ratio 95% CI p-value
8p12 0.925 0.15
Non Amplified 1
Amplified 2.52 (0.72–8.79)
Ki67 1.29 0.055
<20 1
≥20 3.63 (0.97–13.52)
Amplification status and associated metastasis-free survival in breast cancerFigure 3
Amplification status and associated metastasis-free survival in breast cancer. A. Impact of the amplification of 8p12 
region on MFS of the whole population (N = 219). B. Impact of the amplification of 8p12 region on MFS of N- patients (N = 
114). C. Impact of the amplification of 17q12 region on MFS of the whole population (N = 272). D. Impact of the amplification 
of 17q12 region on MFS of N- patients (N = 140). E. Impact of the co-amplification of 8p12 and 17q12 regions on MFS of N- 
patients (N = 84). Kaplan-Meier curves illustrate MFS according to the status of amplification of different regions analyzed.
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was correlated with the absence of estrogen receptor,
which is in agreement with other studies [21,55] but con-
tradictory to others [56,57]. No correlation was found
with hormonotherapy (data not shown). With respect to
prognosis, MYC amplification was not associated with
MFS, neither in the whole population nor in the two dif-
ferent lymph node populations of patients. This is consist-
ent with a previous study [58].
Amplification of the 11q13 region is a relatively frequent
event in breast tumors [59]. This region harbors four dis-
tinct subregions of amplification, which can be amplified
independently or together in different combinations
[59,60]. Candidate genes have been suggested such as
CCND1, EMS1, and PAK1 [60]. Amplification of CCND1
is within the most frequently amplified subregion and is
found in two-thirds of all 11q13 amplifications. CCND1
overexpression promotes tumorigenesis in transgenic
mice [61]. Amplification could promote sustained expres-
sion, which may cause the cell to cycle continuously.
Amplification of CCND1 was found in 19.6% which is
close to what is usually found in breast tumors. No asso-
ciation with histoclinical factors or survival was found, in
disagreement with published data [22,62].
Amplification of 12p13 in breast cancers was first identi-
fied by Dib et al. (1994) [6] and characterized by compar-
ative genomic hybridization by Yao et al. (2006) [7].
Overexpression of presumptive amplicon genes was
found in medullary breast cancers [25]. Amplification of
the short arm of chromosome 12, mostly as isochromo-
some, or as amplified 12p11-12 and 12p13 regions, is a
hallmark of testicular germ cell tumors (TGCT) [63-65]
and its overrepresentation is related to invasive growth of
TGCT [66]. The 12p13 region harbors several candidate
cancer genes. Human embryonic stem cell genes NANOG,
GDF3 and STELLA, which are downregulated when cells
commit differentiation, are expressed in TGCT and in
breast cancers [67,68]. This suggests a role of these stem
cell genes in carcinoma progression. Like CCND1, the
CCND2 protein is involved in G1 phase of the cell cycle.
NOL1 encodes the nucleolar protein P120, a prolifera-
tion-associated antigen that is temporally regulated dur-
ing the cell cycle with an increase in protein expression at
the G1/S transition. The choice of the NOL1 region for
FISH was further suggested because its protein expression
is associated with overall survival in node-negative breast
cancers [69]. However, we did not find any association
between amplification and survival. The 12p13 amplicon
was correlated with 20q13Z, which may also be associated
with proliferation.
ERBB2 amplification was found in 9.9% of tumors and
was associated with high grade, absence of steroid recep-
tors, overexpression of ERBB2 protein, and high prolifera-
tion index, which is an agreement with previous studies
[17,70,71]. In univariate analysis, ERBB2 amplification
was associated with MFS in the whole population and in
N- patients. This is consistent with a poor outcome
reported in several studies [43,71-73].
We found the 20q13 region amplified in 8.5–9.9% of
tumors, which is consistent with frequencies previously
reported in sporadic breast cancers [3,27-29] as well as in
familial breast cancer [74]. The 20q13 amplified region
was associated with 8q24, 11q13 and 12p13 amplifica-
tions. Co-amplification of 11q13/20q13 occurred in 1.6%
of cases. The 20q13Co amplification was associated with
high grade and axillary lymph node invasion, in agree-
ment with previous studies [27,29]. Amplification of
Table 5: Correlation between the amplification and molecular breast subtypes.
Region of 
amplification
Basal Non Basal p-value ERBB2 Non ERBB2 p-value Luminal A Non 
Luminal A
p-value
No. of patients (%) No. of patients (%) No. of patients (%)
11q13
Amplification 1 (5.5) 22 (45.8) p = 0.006 2 (25) 21 (36.2) NS 19 (57.6) 4 (12.1) p = 0.0003
No 
Amplification
17 (94.5) 26 (54.2) 6 (75) 37 (63.8) 14 (42.4) 29 (87.9)
12p13
Amplification 5 (27.8) 2 (4.2) p = 0.02 1 (11.1) 6 (10.5) NS 1 (3.1) 6 (17.6) NS
No 
Amplification
13 (72.2) 46 (95.8) 8 (88.9) 51 (89.5) 31 (96.9) 28 (82.4)
17q12
Amplification 0 (0) 6 (17.6) NS 5 (71.4) 1 (2.2) p = 2.061e-
06
0 (0) 6 (20) NS
No 
Amplification
19 (100) 28 (82.4) 2 (28.6) 45 (97.8) 23 (100) 24 (80) p = 0.065
NS: Not significant
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20q13Z was associated with progesterone receptor nega-
tivity and with an accumulation of P53 in cells. Aberrant
expression of 20q13 genes may be selected during breast
cancer progression because it allows breast cells to over-
come senescence and/or apoptosis. This is likely to be due
to ZNF217 which promotes immortalization of human
mammary epithelial cells [33] and plays a role in sup-
pressing apoptosis [34]. Overexpression of other genes
such as AURKA or MYBL2, which encode proteins
involved in cell cycle regulation, could generate genomic
instability. This accumulation of alterations could then
lead to an increased sensitivity to chemotherapy and may
explain the better prognosis for patients with amplified
20q13Co region [29].
Amplifications and molecular subtypes
We found that the 12p13 amplification was correlated
with the basal subtype, which is in agreement with previ-
ous expression profiling data [25]. Moreover, the 12p13
amplification was correlated with high grade, absence of
steroid receptors and high proliferation index, which are
all features of the basal subtype. In contrast, the 11q13
(CCND1) amplification was negatively correlated with
the basal subtype and strongly correlated with the luminal
A subtype. This is consistent with a previous study [75]
that found an inverse correlation between basal-like
markers and CCND1 amplification.
Conclusion
Our results show that regional amplification and co-
amplification can be associated with pejorative evolution
of breast cancer. Prognosis relevance applies for 8p12 and
17q12 amplifications analyzed as individual variable, and
for 8p12/17q12 co-amplification. The 8p12 region has
the most important impact on clinical outcome in two
populations of patients: whole and axillary lymph node-
negative. Therefore, 8p12 amplification could be used as
a marker of adverse evolution in good prognosis breast
cancer.
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